EAST NORRITON, Pa., June 17 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN) today announced that it has presented new preclinical data at the 8th Annual Meeting of the International Society for Stem Cell Research (ISSCR) being held June 16-19 in San Francisco. These data, highlighted during the meeting's poster session on June 16, show the important distinction between adipose-derived smooth muscle cells (SMCs) and mesenchymal stem cells (MSCs). The Tengion data demonstrate that SMC's sourced from adipose tissue, which have been demonstrated to promote regeneration of tubular tissues and hollow organs, have protein and gene expression profiles distinct from those generated by MSCs. Tengion's Neo-Urinary Conduit™, currently in Phase 1 clinical development, is utilizing the Tengion's proprietary adipose-derived SMC technology.
"Our continued generation of key preclinical data further demonstrates mechanisms of natural regeneration promoted by Tengion's technology platform," stated Tim Bertram, D.V.M., Ph.D., Senior Vice President of Science and Technology for Tengion. Tengion's lead product candidate, the Neo-Urinary Conduit, is currently in an open-label, single arm Phase I clinical trial in patients with bladder cancer. The Neo-Urinary Conduit is an autologous – made from a patient's own cells – implant that is intended to catalyze the regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal.
|SOURCE Tengion Inc.|
Copyright©2010 PR Newswire.
All rights reserved